Qlarity Imaging Named a Top 10 Medical Imaging Solutions Provider by Healthcare Tech Outlook
The company honored for its innovative diagnostic AI technology QuantX to improve breast cancer detection and diagnosis.
- Chicago, IL (1888PressRelease) August 03, 2020 - Qlarity Imaging, a leading innovator in artificial intelligence (AI) diagnostics dedicated to transforming women’s imaging, has been named a Top 10 Medical Imaging Solutions Provider by Healthcare Tech Outlook. Among the various accomplishments contributing to the award, the company developed QuantX—the first U.S. Food and Drug Administration (FDA)-cleared diagnostic AI software—which assists radiologists in the assessment and characterization of breast abnormalities during MRI evaluations.
“Our team is committed to disrupting the status quo in search of a more accurate solution to detect and diagnose breast cancer that will benefit the hundreds of thousands of women annually diagnosed with this devastating disease,” said Jon DeVries, chief executive officer of Qlarity Imaging. “By using artificial intelligence to analyze data that is not visible to the human eye, QuantX helps radiologists make more informed decisions and reduces the likelihood of misdiagnosis, ultimately leading to improved patient care.”
Understanding the many complex challenges radiologists encounter when reading medical images, Healthcare Tech Outlook identified companies that exhibit true innovation and provide unique imaging solutions within the healthcare sector. A panel of CEOs, CIOs, and industry analysts selected Qlarity Imaging, a portfolio company of Paragon Biosciences, for the effectiveness of QuantX in reducing missed cancers by 39% and improving overall diagnostic performance by 20% compared to traditional methods of MRI interpretation. In addition, Qlarity Imaging is being recognized for its vision to expand its diagnostic AI technology across all modalities in women’s imaging.
“With its life-changing technology, Qlarity Imaging mirrors the same passion as Paragon Biosciences—life science innovators, seeking to improve the quality of life through scientific breakthroughs,” said Jeff Aronin, founder, chairman and chief executive officer of Paragon Biosciences. “Qlarity is delivering vital breast imaging tools to radiologists and health systems to enhance patient care until this devastating disease is conquered and eliminated.”
Furthering its commitment to innovation, Qlarity Imaging recently announced a partnership with Ikonopedia to help improve breast cancer diagnosis and reporting accuracy through an integrated software solution.
QuantX has received numerous accolades since its release, including being named one of TIME’s 100 Best Inventions of 2019, a 2020 Gold Edison Award, and contributing to Paragon’s recognition as one of Fast Company’s 10 Most Innovative Health Companies of 2020.
To read more about Qlarity Imaging and Healthcare Tech Outlook’s Top 10 Medical Imaging Solutions Provider award program, please visit www.medical-imaging.healthcaretechoutlook.com/vendors/top-medical-imaging-solution-companies.com.
About Qlarity Imaging
Qlarity Imaging improves patient care by building AI-driven breast imaging solutions that enhance diagnostic insights. The company’s vision is to transform women’s imaging with AI technologies that advance the detection and diagnosis of breast cancer. Qlarity’s award-winning initial product, QuantX, is the first computer-aided diagnosis software to be cleared by the FDA for breast MRI evaluation. Qlarity Imaging was founded by Paragon Biosciences, a life science innovator that creates, invests in and builds life science companies in artificial intelligence, cell and gene therapy, synthetic biology and biopharmaceuticals. For more information, please visit www.qlarityimaging.com.
Indication: QuantX is indicated for evaluation of the assessment and characterization of breast abnormalities from MRI data in patients presenting for high-risk screening, diagnostic imaging workup, or evaluation of extent of known disease. QuantX is not intended for primary interpretation of digital mammography images.
Important Safety Statement: QuantX is not intended for primary interpretation of digital mammography images. Warnings and cautions related to the potential device failure or low performance are included in the User Manual including comments on image quality, patient population, and segmentation accuracy. Warnings and cautions related to the device are included in the User Manual. Information about the Similar Case Database and cases used in the MRMC study provided in labeling also provide information to users about potential limitations of the device related to specific subpopulations.
About Paragon Biosciences
Qlarity Imaging is a portfolio company of Paragon Biosciences. Paragon is a life science innovator that creates, invests in and builds life science companies in artificial intelligence, cell and gene therapy, synthetic biology and biopharmaceuticals. Our current portfolio includes Castle Creek Biosciences, Emalex Biosciences, Evozyne, Harmony Biosciences, Qlarity Imaging, Skyline Biosciences, and a consistent flow of incubating companies created and supported by our replicable Paragon Innovation Capital™ model. Paragon stands at the intersection of human need, life science, and company creation. For more information, please visit https://paragonbiosci.com/.
About Healthcare Tech Outlook
Healthcare Tech Outlook is a print platform offering healthcare decision makers critical information on adopting, innovating, and building new programs and approaches to enhance their capability to provide care. The organization has been a pioneer in offering a learn-from-peer approach to the healthcare arena, offering technology advice to improve both the overall healthcare landscape and assist individual care providers. For more information, please visit https://www.healthcaretechoutlook.com/.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam